Metabolic abnormalities lead to the dysfunction of metabolic pathways and metabolite
accumulation or deficiency which is well-recognized hallmarks of diseases. Metabolite …

Our increased understanding of how key metabolic pathways are activated and regulated in
malignant cells has identified metabolic vulnerabilities of cancers. Translating this insight to …

Background Increasing evidence implicates microbiome involvement in the development
and progression of pancreatic ductal adenocarcinoma (PDAC). Studies suggest that reflux of …

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with five-year
survival rates around 10%. The only curative option remains complete surgical resection, but …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a poor
prognosis, largely due to its unique tumor microenvironment (TME) and dense fibrotic …

Mothers influence the health and disease trajectories of their children, particularly during the
critical developmental windows of fetal and neonatal life reflecting the gestational–fetal and …

Pancreatic ductal adenocarcinoma (PDAC) is difficult to diagnose in the early stages and
lacks reliable biomarkers. The scope of this project was to establish quantitative nuclear …

Introduction In the dynamic landscape of modern healthcare, the ability to anticipate and
diagnose diseases, particularly in cases where early treatment significantly impacts …

Background Our aim was to investigate the rationality and accuracy of plasma TrxR activity
as an efficient tool in the early diagnosis of gastrointestinal malignancy, and whether TrxR …

Pancreatic ductal adenocarcinoma (PDAC) is a solid-tumor malignancy. To enhance the
treatment landscape of PDAC, a 3D model optimized for rigorous drug screening is …